Le Lézard
Classified in: Health
Subjects: CCA, PER, MAT

AUXLY TO REPORT THIRD QUARTER 2023 FINANCIAL RESULTS ON NOVEMBER 13, 2023


TORONTO, Nov. 6, 2023 /CNW/ - Auxly Cannabis Group Inc. (TSX: XLY) (OTCQB: CBWTF) ("Auxly" or the "Company"), a leading consumer packaged goods company in the cannabis products market, announced today that it will report earnings results for its third quarter 2023 ended September 30, 2023, on Monday, November 13, 2023, before the financial markets open.

The Company will not host an earnings conference call and the Company does not anticipate reinstating earnings conference calls until further notice. All investor inquiries should be directed to [email protected].

ON BEHALF OF THE BOARD

"Hugo Alves" CEO

About Auxly Cannabis Group Inc. (TSX: XLY)

Auxly is a leading Canadian consumer packaged goods company in the cannabis products market, headquartered in Toronto, Canada. The Company's focus is on developing, manufacturing and distributing branded cannabis products that delight our consumers.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Auxly Cannabis Group Inc. logo (CNW Group/Auxly Cannabis Group Inc.)

SOURCE Auxly Cannabis Group Inc.


These press releases may also interest you

at 16:20
Verastem Oncology, , a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock,...

at 16:20
Geron Corporation , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart...

at 16:15
Exelixis, Inc. announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss...

at 16:15
Nuvation Bio Inc. , a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced multiple updates for its taletrectinib program. Data from the global, pivotal Phase 2 TRUST-II study...

at 16:15
The Board of Directors of BD (Becton, Dickinson and Company) , a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on...

at 16:05
Ligand Pharmaceuticals Incorporated today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that...



News published on and distributed by: